Latest Biotech News

A retrospective real-world analysis reports that sustained Zepbound (tirzepatide) use in adults over age 55 with obesity is associated with lower healthcare utilization and reduced costs. The...

Boehringer Ingelheim’s investigational dual GLP-1 and glucagon receptor agonist survodutide delivered significantly greater weight loss than placebo in a phase 3 trial in adults with obesity...

Bristol Myers Squibb has ended its partnership with cell therapy manufacturing startup Cellares, saying its Cell Shuttle commercial manufacturing technology did not meet expectations. Cellares...

Boston Scientific disclosed that a cyberattack disrupted parts of its IT systems and order-shipping capabilities, and the company could not immediately provide a timeline for full restoration. The...

Researchers reported preclinical results for syncytial CAR macrophages that fuse CAR-engineered macrophages with neutrophils to increase tumor penetration and immune activity. Published in Nature...

Polaryx Therapeutics raised $10 million and is moving PLX-200, an oral reformulation of gemfibrozil, into an open-label phase II basket trial spanning four ultra-rare pediatric lysosomal storage...

Haisco Pharmaceutical expanded its newco strategy by launching Sentivera and initiating a high-value licensing effort tied to oral therapies for inflammatory diseases. Sentivera was formed through...

FDA clearance of a Roche and Eli Lilly Alzheimer’s blood test expands access to a single-biomarker approach for assessing amyloid pathology. The Elecsys pTau217 test cleared by the FDA is intended...

Spyre Therapeutics is deprioritizing its TL1A antibody monotherapy program in rheumatoid arthritis after phase 2 results failed to meet the company’s success bar. The update follows SPY072’s...

The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma, positioning the once-daily, oral pan-RAS inhibitor as the first RAS-targeting therapy...

McKesson signed a definitive agreement to acquire Precision Medicine Group for about $2.25 billion, aiming to deepen its oncology and clinical research services. The deal, structured as an...

Boston Scientific disclosed that a cyberattack disrupted its global IT systems and affected its ability to process and ship customer orders, without providing a timeline for full restoration. The...

Polaryx Therapeutics raised $10 million after a Nasdaq listing and is moving PLX-200—an oral gemfibrozil reformulation—into an open-label Phase 2 basket trial across four ultra-rare pediatric...

Biohaven secured a commercial partner for its late-stage epilepsy platform after South Korea’s SK Biopharmaceuticals offered up to $795 million for global rights to Biohaven’s Kv7 ion channel...

Faro raised a $37 million Series B to accelerate clinical trials using AI, targeting a known bottleneck: the time and complexity required to operate through trial execution rather than to design...

Cellares rebuffed Bristol Myers Squibb’s criticism of its cell therapy manufacturing technology after BMS terminated a contract, citing concerns about commercial manufacturing readiness. Cellares...

Spyre Therapeutics said it is deprioritizing its anti-TL1A rheumatoid arthritis antibody SPY072 after Phase 2 monotherapy results missed its success bar. The company framed the decision as a shift...

Kite Pharma, a Gilead company, developed a technique for analyzing individual lentiviral vector particles using flow virometry—an approach intended to support more detailed characterization of in...

The U.S. Federal Trade Commission flagged that licensing of pending patents can create antitrust risk, filing an amicus brief in the Fourth Circuit tied to Amgen’s long-running exclusive rights to...

The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque), a two-pills-a-day targeted treatment for metastatic pancreatic cancer patients whose disease has progressed after chemotherapy....